title: Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.
abstract: OBJECTIVE
  To determine whether prophylactic, low dose controlled-release aspirin improves outcome for pregnant women and their babies in Barbados.
  
  
  METHODS
  Randomised placebo-controlled trial.
  
  
  METHODS
  The Queen Elizabeth Hospital, Barbados.
  
  
  METHODS
  All women attending antenatal clinics between 12 and 32 weeks of gestation were eligible, if without specific contraindications to aspirin and unlikely to deliver immediately.
  
  
  METHODS
  Randomisation was computer-generated in the antenatal clinic; 1822 women were allocated to receive 75 mg controlled-release aspirin and 1825 matching placebo.
  
  
  METHODS
  Proteinuric pre-eclampsia, other pregnancy-induced hypertension, pregnancy duration, birthweight, stillbirths and neonatal deaths, major neonatal events.
  
  
  RESULTS
  All but three women from each group were followed up successfully. Forty-four percent were primigravid, and 8% had previous obstetric complications. There were no significant differences between the allocated treatment groups in the incidence of proteinuric pre-eclampsia (40 [2.2%] of those allocated aspirin, compared with 46 [2.5%] allocated placebo), of preterm delivery (255 [14.0%] vs 270 [14.8%]), of birthweight < 1500 g (32 [1.7%] vs 33 [1.8%]) or of stillbirth and neonatal death (44 [2.4%] vs 38 [2.1%]). Aspirin was not associated with excess risk of maternal or fetal bleeding.
  
  
  CONCLUSIONS
  The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings.
authors.affiliation: Faculty of Medical Sciences, University of the West Indies, Queen Elizabeth Hospital, Barbados.
authors.forename: Y E
authors.initials: YE
authors.lastname: Rotchell
authors.forename: J K
authors.initials: JK
authors.lastname: Cruickshank
authors.forename: M P
authors.initials: MP
authors.lastname: Gay
authors.forename: J
authors.initials: J
authors.lastname: Griffiths
authors.forename: A
authors.initials: A
authors.lastname: Stewart
authors.forename: B
authors.initials: B
authors.lastname: Farrell
authors.forename: S
authors.initials: S
authors.lastname: Ayers
authors.forename: A
authors.initials: A
authors.lastname: Hennis
authors.forename: A
authors.initials: A
authors.lastname: Grant
authors.forename: L
authors.initials: L
authors.lastname: Duley
authors.forename: R
authors.initials: R
authors.lastname: Collins
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D001460:Barbados / Q000453:epidemiology; D001724:Birth Weight; D003692:Delayed-Action Preparations; D005260:Female; D005313:Fetal Death; D005865:Gestational Age; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D007231:Infant, Newborn; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011225:Pre-Eclampsia / Q000517:prevention & control*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011295:Prenatal Care; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin